BIOMERICA INC (BMRA) Fundamental Analysis & Valuation

NASDAQ:BMRA • US09061H4065

Current stock price

2.05 USD
+0.04 (+1.99%)
Last:

This BMRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BMRA Profitability Analysis

1.1 Basic Checks

  • In the past year BMRA has reported negative net income.
  • In the past year BMRA has reported a negative cash flow from operations.
  • BMRA had negative earnings in each of the past 5 years.
  • BMRA had a negative operating cash flow in each of the past 5 years.
BMRA Yearly Net Income VS EBIT VS OCF VS FCFBMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

  • With a Return On Assets value of -66.71%, BMRA is not doing good in the industry: 72.34% of the companies in the same industry are doing better.
  • BMRA has a Return On Equity of -90.76%. This is in the lower half of the industry: BMRA underperforms 62.23% of its industry peers.
Industry RankSector Rank
ROA -66.71%
ROE -90.76%
ROIC N/A
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
BMRA Yearly ROA, ROE, ROICBMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Gross Margin of BMRA (5.61%) is worse than 80.32% of its industry peers.
  • BMRA's Gross Margin has declined in the last couple of years.
  • BMRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
BMRA Yearly Profit, Operating, Gross MarginsBMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BMRA Health Analysis

2.1 Basic Checks

  • BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BMRA has more shares outstanding than it did 1 year ago.
  • BMRA has more shares outstanding than it did 5 years ago.
  • BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BMRA Yearly Shares OutstandingBMRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
BMRA Yearly Total Debt VS Total AssetsBMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -11.74, we must say that BMRA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -11.74, BMRA is doing worse than 80.85% of the companies in the same industry.
  • BMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.74
ROIC/WACCN/A
WACC10.6%
BMRA Yearly LT Debt VS Equity VS FCFBMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 3.25 indicates that BMRA has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.25, BMRA perfoms like the industry average, outperforming 57.45% of the companies in the same industry.
  • BMRA has a Quick Ratio of 2.29. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
  • BMRA has a Quick ratio of 2.29. This is comparable to the rest of the industry: BMRA outperforms 56.38% of its industry peers.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 2.29
BMRA Yearly Current Assets VS Current LiabilitesBMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. BMRA Growth Analysis

3.1 Past

  • BMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.20%, which is quite impressive.
  • The Revenue for BMRA has decreased by -20.05% in the past year. This is quite bad
  • The Revenue has been decreasing by -4.51% on average over the past years.
EPS 1Y (TTM)38.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.25%
Revenue 1Y (TTM)-20.05%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-26.04%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMRA Yearly Revenue VS EstimatesBMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
BMRA Yearly EPS VS EstimatesBMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. BMRA Valuation Analysis

4.1 Price/Earnings Ratio

  • BMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMRA Price Earnings VS Forward Price EarningsBMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMRA Per share dataBMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BMRA Dividend Analysis

5.1 Amount

  • BMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BMRA Fundamentals: All Metrics, Ratios and Statistics

BIOMERICA INC

NASDAQ:BMRA (3/30/2026, 8:00:02 PM)

2.05

+0.04 (+1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-12
Earnings (Next)04-13
Inst Owners2.96%
Inst Owner Change0.74%
Ins Owners14.06%
Ins Owner Change0%
Market Cap6.19M
Revenue(TTM)4.46M
Net Income(TTM)-4.03M
Analysts85.71
Price TargetN/A
Short Float %1.77%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.39
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS1.48
BVpS1.47
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -66.71%
ROE -90.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.61%
FCFM N/A
ROA(3y)-65.89%
ROA(5y)-60.11%
ROE(3y)-90.92%
ROE(5y)-81.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.95%
GM growth 5Y-18.46%
F-Score4
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.76%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 2.29
Altman-Z -11.74
F-Score4
WACC10.6%
ROIC/WACCN/A
Cap/Depr(3y)94.83%
Cap/Depr(5y)109.76%
Cap/Sales(3y)1.44%
Cap/Sales(5y)1.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-20.05%
Revenue growth 3Y-34.47%
Revenue growth 5Y-4.51%
Sales Q2Q%-26.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.94%
OCF growth 3YN/A
OCF growth 5YN/A

BIOMERICA INC / BMRA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOMERICA INC?

ChartMill assigns a fundamental rating of 2 / 10 to BMRA.


What is the valuation status for BMRA stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOMERICA INC (BMRA). This can be considered as Overvalued.


Can you provide the profitability details for BIOMERICA INC?

BIOMERICA INC (BMRA) has a profitability rating of 0 / 10.


Can you provide the financial health for BMRA stock?

The financial health rating of BIOMERICA INC (BMRA) is 6 / 10.